A Case Report of Lynch Syndrome: Clinical Course and Literature Review

Di Wang; Xuyou Liu

doi:10.54097/hdw7em07

Authors

Di Wang
Xuyou Liu

DOI:

https://doi.org/10.54097/hdw7em07

Keywords:

Lynch Syndrome, Small Bowel Adenocarcinoma, Microsatellite Instability, Immunotherapy

Abstract

Lynch syndrome (LS) is a hereditary cancer predisposition syndrome caused by germline defects in DNA mismatch repair (MMR) genes. While colorectal cancer is its most common manifestation, small bowel adenocarcinoma (SBA) remains a rare occurrence and often presents with nonspecific symptoms, contributing to delayed diagnosis. We present the case of a 76-year-old woman with Lynch syndrome who initially presented with anorexia, fatigue, and abdominal pain. Initial gastroscopy and colonoscopy were unrevealing. However, with progressive symptoms and rising tumor markers, further evaluation with positron emission tomography–computed tomography (PET-CT) and double-balloon enteroscopy led to the diagnosis of moderately differentiated duodenal adenocarcinoma. Immunohistochemical analysis confirmed microsatellite instability (MSI). Given her personal and family history of colorectal neoplasms, a clinical diagnosis of Lynch syndrome was established. The patient exhibited poor tolerance to platinum-based chemotherapy and was subsequently treated with a programmed cell death protein 1 (PD-1) inhibitor, resulting in transient clinical improvement. In the later course, her illness was complicated by exacerbation of pre-existing Sjögren’s syndrome and severe opportunistic infections, culminating in acute respiratory distress syndrome and multiorgan failure, ultimately leading to death. This case highlights the elevated risk of multiple primary malignancies in Lynch syndrome, the diagnostic challenges associated with SBA, and the pivotal role of MSI status in guiding immunotherapy. It also underscores the need for careful monitoring of immune-related adverse events, particularly in patients with underlying autoimmune diseases.

Downloads

Download data is not yet available.

References

[1] Boland PM, Yurgelun MB, Boland CR. Recent progress in lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018 May;68(3):217–31.

[2] Peltomäki P, Nyström M, Mecklin JP, Seppälä TT. Lynch syndrome genetics and clinical implications. Gastroenterology. 2023 Apr 1;164(5):783–99.

[3] Maratt JK, Rubenstein JH. Tailoring colorectal cancer surveillance in lynch syndrome: More is not always better. Gastroenterology. 2021 Aug;161(2):411–2.

[4] American Gastroenterological Association. Lynch syndrome: AGA patient guideline summary. Gastroenterology. 2015 Sept;149(3):814–5.

[5] Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018 Aug 23;379(8):764–73.

[6] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clinicians. 2024 Jan;74(1):12–49.

[7] Zhang S, Gu Y. Advances in the diagnosis and management of small bowel diseases in 2023. Theory and Practice of Diagnostics. 2024;23(2):119–125.

[8] Koornstra JJ, Kleibeuker JH, Vasen HFA. Small-bowel cancer in lynch syndrome: Is it time for surveillance? Lancet Oncol. 2008 Sept;9(9):901–5.

[9] Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, et al. Guidelines for the management of hereditary colorectal cancer from the british society of gastroenterology (BSG)/association of coloproctology of great britain and ireland (ACPGBI)/united kingdom cancer genetics group (UKCGG). Gut. 2020 Mar;69(3):411–44.

[10] Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of lynch syndrome. J Pathol. 2020 Apr;250(5):518–31.

[11] Liu J, Wu G, Xiao X, Li J. Advances in research on primary small bowel tumors. Contemporary Medicine. 2020;26(10): 188–191.

[12] Seppälä TT, Latchford A, Negoi I, Sampaio Soares A, Jimenez-Rodriguez R, Sánchez-Guillén L, et al. European guidelines from the EHTG and ESCP for lynch syndrome: An updated third edition of the mallorca guidelines based on gene and gender. Br J Surg. 2021 May 27;108(5):484–98.

[13] Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of lynch syndrome: 1895-2015. Nat Rev Cancer. 2015 Mar;15(3):181–94.

[14] Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017 Nov 1;3(11):1546–53.

[15] Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2019 Sept 1;17(9):1109–33.

[16] Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019 Aug 1;30(8):1232–43.

[17] Alfagih A, Alrehaili M, Asmis T. Small bowel adenocarcinoma: 10-year experience in a cancer center-the ottawa hospital (TOH). Curr Oncol. 2022 Oct 5;29(10):7439–49.

[18] Cronin CG, Scott J, Kambadakone A, Catalano OA, Sahani D, Blake MA, et al. Utility of positron emission tomography/CT in the evaluation of small bowel pathology. Br J Radiol. 2012 Sept;85(1017):1211–21.

[19] Kupfer SS. Broadening our understanding of the immune landscape in lynch syndrome. Gastroenterology. 2022 Apr; 162 (4):1024–5.

[20] Xuan H, Cao L, Zhan S. Advances in biomarkers for evaluating the efficacy of PD-1/PD-L1–targeted immunotherapy. Huaxia Medicine. 2025;38(3):29–37. doi:10.19296/j.cnki.1008-2409. 2025-03-004.

[21] Mei W, Wang X, Xing X, et al. Advances and emerging directions in cancer immunotherapy. Chinese Science Foundation. 2025;39(1):60–69. doi:10.16262/j.cnki.1000-8217. 20250227.009.

[22] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 June 25;372(26):2509–20.

[23] Harrold EC, Foote MB, Rousseau B, Walch H, Kemel Y, Richards AL, et al. Neoplasia risk in patients with lynch syndrome treated with immune checkpoint blockade. Nat Med. 2023 Oct;29(10):2458–63.

[24] Symons R, Daly D, Gandy R, Goldstein D, Aghmesheh M. Progress in the Treatment of Small Intestine Cancer. Curr Treat Options in Oncol. 2023 Apr;24(4):241–61.

[25] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 July 28;357 (6349): 409–13.